BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramírez-de-Arellano A, Villegas-Pineda JC, Hernández-Silva CD, Pereira-Suárez AL. The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers. Front Endocrinol (Lausanne) 2021;12:747810. [PMID: 34745013 DOI: 10.3389/fendo.2021.747810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Standing D, Dandawate P, Anant S. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies. Front Endocrinol 2023;13. [DOI: 10.3389/fendo.2022.1112987] [Reference Citation Analysis]
2 Kavarthapu R, Dufau ML. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness. Front Endocrinol 2022;13:949396. [DOI: 10.3389/fendo.2022.949396] [Reference Citation Analysis]
3 Treeck O, Weber F, Fritsch J, Skrzypczak M, Schüler-toprak S, Buechler C, Ortmann O. DSCAM-AS1 Long Non-Coding RNA Exerts Oncogenic Functions in Endometrial Adenocarcinoma via Activation of a Tumor-Promoting Transcriptome Profile. Biomedicines 2022;10:1727. [DOI: 10.3390/biomedicines10071727] [Reference Citation Analysis]
4 Chiang J, Lei F, Chang H, Wei S, Wang C, Huang Y, Wang H, Chuang C, Hu S, Hsieh C. Haloperidol Instigates Endometrial Carcinogenesis and Cancer Progression by the NF-κB/CSF-1 Signaling Cascade. Cancers 2022;14:3089. [DOI: 10.3390/cancers14133089] [Reference Citation Analysis]
5 Watrowski R, Obermayr E, Wallisch C, Aust S, Concin N, Braicu EI, Van Gorp T, Hasenburg A, Sehouli J, Vergote I, Zeillinger R. Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. Cancers 2022;14:1780. [DOI: 10.3390/cancers14071780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]